Data from the pivotal GLOW trial presented at the Endocrine Society's annual meeting show that Gelesis' Gelesis100 non-systemic, superabsorbent hydrogel significantly reduces insulin-resistance compared to placebo in overweight and obese patients.
New results from the GLOW trial show Gelesis’ Gelesis100 superabsorbent hydrogel can reduce insulin resistance in overweight and obese patients, independent of their starting weight.
Frank Greenway of Pennington Biomedical Research Center in Baton Rouge presented results from GLOW at the Endocrine Society’s ENDO 2019 meeting in New Orleans, March 25.
The FDA has stopped accepting data from two Chinese labs due to accuracy issues. Mid-Link and SDWH have been flagged for potentially falsified results and other misconduct. This decision, which follows months of discussions and warnings, emphasizes the FDA's commitment to ensuring data integrity in medical device submissions.
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
